Immunodeficiency 82 With Systemic Inflammation (IMD82) — Comprehensive Disease Characterization Report

Target Disease: Immunodeficiency 82 With Systemic Inflammation OMIM: #619381 · MONDO: MONDO:0030308 · Causal gene: SYK (HGNC:11491) Category: Mendelian (monogenic inborn error of immunity)

Summary

Immunodeficiency 82 with systemic inflammation (IMD82) is an ultra-rare, autosomal dominant inborn error of immunity (IEI) caused by germline heterozygous gain-of-function (GOF) missense variants in SYK (spleen tyrosine kinase). The disease was defined in 2021 by Wang and colleagues, who identified damaging monoallelic SYK variants in six patients presenting with a distinctive triad: immune deficiency, multi-organ inflammatory disease (colitis, arthritis, dermatitis), and diffuse large B-cell lymphoma (DLBCL) (PMID: 33782605). The variants increase SYK phosphorylation and enhance downstream signaling, establishing a gain-of-function mechanism.

Mechanistically, SYK is normally held in an autoinhibited conformation in which its tandem SH2 (tSH2) domain and interdomain linkers constrain the kinase domain. Binding of phosphorylated immunoreceptor tyrosine-based activation motifs (pITAMs) plus autophosphorylation switches SYK to its active state (PMID: 23154170). IMD82 variants bias SYK toward the active conformation, producing constitutive ITAM-based signaling through PLCγ2, PI3K–AKT, MAPK/ERK, and NF-κB. This single hyperactive-kinase lesion simultaneously drives the inflammatory arm (excess cytokine/immune-cell activation) and the malignant arm (sustained pro-survival BCR/PI3K signaling that predisposes B cells to lymphoma).

Because the driver is a druggable, hematopoietically restricted kinase, IMD82 is potentially treatable. A knock-in Syk-Ser544Tyr mouse (modeling the patient variant p.Ser550Tyr) recapitulated key disease features that could be partially corrected either with a SYK inhibitor or with transplantation of wild-type bone marrow (PMID: 33782605). Fostamatinib, an FDA-approved oral SYK inhibitor (approved for chronic immune thrombocytopenia), provides a clinically available agent whose mechanism directly matches the disease lesion. Diagnosis relies on next-generation sequencing (whole-exome/whole-genome sequencing or IEI gene panels) with confirmatory functional testing of elevated SYK phosphorylation/downstream signaling. Only ~6 patients have been reported worldwide, so much of the clinical natural history remains to be defined.

Key Findings

Finding 1 — IMD82 is caused by monoallelic gain-of-function variants in SYK

Wang et al. (2021, Nature Genetics) identified damaging monoallelic (heterozygous) SYK variants in six patients. Functional assays demonstrated that the variants increased SYK phosphorylation and enhanced downstream signaling, formally establishing a gain-of-function (rather than loss-of-function) mechanism and an autosomal dominant mode of inheritance. This is the defining genetic feature of the disease and is catalogued as OMIM #619381 / MONDO:0030308.

"We identified damaging monoallelic SYK variants in six patients with immune deficiency, multi-organ inflammatory disease such as colitis, arthritis and dermatitis, and diffuse large B cell lymphomas. The SYK variants increased phosphorylation and enhanced downstream signaling, indicating gain of function." — PMID: 33782605

This finding is notable because most SYK-related disease hypotheses historically concerned loss of function; IMD82 is a rare instance where a kinase gain-of-function drives a combined immunodeficiency-plus-autoinflammation syndrome.

Finding 2 — SYK is normally autoinhibited; GOF variants disrupt the activation switch

Crystal structures of full-length SYK reveal an autoinhibited conformation in which the tandem SH2 (tSH2) domain and interdomain linkers restrain kinase activity. Binding of phosphorylated ITAMs to the tSH2 domain, together with autophosphorylation of interdomain-A tyrosines (e.g., Y348/Y352), switches SYK to the active conformation and strongly stimulates in vitro autophosphorylation (PMID: 23154170). IMD82 patient variants (e.g., p.Ser550Tyr, and residues in the interdomain-A/kinase regions) constitutively bias this switch toward the active state, producing elevated basal phosphorylation and downstream signaling.

"Here, we present the first crystal structures of full-length Syk (fl-Syk) as wild type and as Y348F,Y352F mutant forms in complex with AMP-PNP revealing an autoinhibited conformation." — PMID: 23154170

"The functional relevance of pITAM binding to fl-Syk was confirmed by a strong stimulation of in vitro autophosphorylation." — PMID: 23154170

This provides a clear structural rationale for the disease: the GOF variants relieve the molecular brake that normally couples SYK activation to receptor engagement.

SYK is the proximal kinase that transduces signals from the B-cell receptor (BCR) and Fc/C-type-lectin receptors into downstream PI3K–AKT, PLCγ2, MAPK/ERK, and NF-κB cascades (PMID: 35398488; PMID: 38503806). Sustained/tonic PI3K-pathway signaling downstream of SYK promotes B-cell survival rather than negative selection, and high SYK/BCR signaling activity predicts aggressive B-cell lymphoma behavior. This mechanistically unifies the two seemingly disparate arms of IMD82 — chronic multi-organ inflammation and predisposition to DLBCL — under a single constitutively active kinase.

"ZAP70 diverts SYK from activation of NFAT towards tonic PI3K-signaling, which promotes survival instead of cell death" — PMID: 35398488

In mantle cell lymphoma, higher BCR/SYK signaling responses correlate with shorter progression-free and overall survival, underscoring that SYK signaling intensity is a determinant of malignant aggressiveness (PMID: 38503806).

Finding 4 — Clinical phenotype: pediatric-onset immunodeficiency + multi-organ autoinflammation + DLBCL

In the defining cohort of six patients, the phenotype combined immune deficiency with multi-organ inflammatory disease — colitis (HP:0002583), arthritis (HP:0001369), and dermatitis (HP:0011123) — plus diffuse large B-cell lymphoma (HP:0004297) (PMID: 33782605). Onset is typically in childhood, frequently as a very-early-onset inflammatory-bowel-disease-like presentation. IMD82/SYK is incorporated into the formal IUIS Inborn Errors of Immunity classification framework used for diagnosis (PMID: 41608114).

"immune deficiency, multi-organ inflammatory disease such as colitis, arthritis and dermatitis, and diffuse large B cell lymphomas" — PMID: 33782605

"This report provides an updated classification of inborn errors of immunity (IEIs) involving 508 different genes and 17 phenocopies." — PMID: 41608114

Finding 5 — Ultra-rare autosomal dominant disorder diagnosed by exome/genome sequencing

Only ~6 patients were reported in the defining publication, and no population prevalence/incidence estimates exist (ultra-rare). Inheritance is autosomal dominant (monoallelic/heterozygous variants), consistent with both de novo and inherited transmission. Diagnosis relies on next-generation sequencing (WES/WGS or IEI gene panels), as used across monogenic VEO-IBD and IEI cohorts, with confirmatory functional assays demonstrating elevated SYK phosphorylation/downstream signaling (PMID: 33782605).

"We identified damaging monoallelic SYK variants in six patients" — PMID: 33782605

Finding 6 — The disease is potentially treatable with SYK inhibition or bone-marrow transplant

A knock-in Syk-Ser544Tyr mouse (modeling patient variant p.Ser550Tyr) recapitulated aspects of the human disease that could be partially treated with a SYK inhibitor or with transplantation of wild-type bone marrow (PMID: 33782605). Fostamatinib is an FDA-approved oral SYK inhibitor (approved for chronic ITP), making targeted pharmacotherapy immediately plausible.

"A knock-in (SYK-Ser544Tyr) mouse model of a patient variant (p.Ser550Tyr) recapitulated aspects of the human disease that could be partially treated with a SYK inhibitor or transplantation of bone marrow from wild-type mice." — PMID: 33782605

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

  1. A germline heterozygous gain-of-function missense variant in SYK (e.g., p.Ser550Tyr) arises de novo or is inherited (autosomal dominant). — demonstrated (PMID: 33782605)
  2. The variant disrupts SYK's autoinhibited conformation — normally maintained by the tSH2 domain and interdomain-A linkers — biasing the kinase toward its active state. — inferred from structure (PMID: 23154170)
  3. This relieves the requirement for pITAM engagement/autophosphorylation, so SYK exhibits elevated basal (constitutive) kinase activity and enhanced phosphorylation independent of full receptor input. — demonstrated (increased pSYK) (PMID: 33782605)
  4. Constitutive SYK activity hyper-transduces ITAM-coupled receptor signals (BCR, Fc receptors, C-type lectin receptors) into downstream cascades: PLCγ2, PI3K–AKT, MAPK/ERK, and NF-κB. — demonstrated/inferred (PMID: 35398488)
  5. The mechanism then branches:
  6. Branch A (autoinflammation/immune dysregulation): Excess NF-κB/MAPK-driven cytokine production and immune-cell activation in myeloid and lymphoid compartments → multi-organ inflammation (colitis, arthritis, dermatitis). Paradoxical immune deficiency co-exists, reflecting dysregulated rather than simply amplified immunity. — demonstrated clinically (PMID: 33782605)
  7. Branch B (lymphomagenesis): Sustained tonic PI3K–AKT survival signaling downstream of SYK promotes B-cell survival over negative selection, permitting accumulation of transformation-prone clones → diffuse large B-cell lymphoma. — inferred from lymphoma biology (PMID: 35398488; PMID: 38503806)
  8. Because the lesion is a hematopoietically restricted, druggable kinase, SYK inhibition (pharmacologic) or replacement of the mutant hematopoietic compartment (WT bone-marrow transplant) partially reverses disease. — demonstrated in mouse (PMID: 33782605)

Schematic

  SYK GOF variant (e.g. p.Ser550Tyr)
              │  disrupts
              ▼
  Autoinhibited SYK  ──X──►  Constitutively ACTIVE SYK
   (tSH2 brake)                    │ hyper-signaling
                                   ▼
        ┌──────────── ITAM-coupled receptor cascades ────────────┐
        │      PLCγ2 · PI3K–AKT · MAPK/ERK · NF-κB                 │
        └──────────────┬───────────────────────┬──────────────────┘
                       │                        │
             BRANCH A (inflammation)     BRANCH B (survival)
             cytokines, immune            tonic PI3K–AKT →
             dysregulation                B-cell survival
                       │                        │
                       ▼                        ▼
        Colitis, arthritis,            Diffuse large B-cell
        dermatitis + immune            lymphoma (DLBCL)
        deficiency
                       │                        │
                       └──── TREATABLE via ─────┘
                     SYK inhibitor (fostamatinib) │ WT BMT/HSCT

Upstream vs downstream

Suggested ontology terms

Section-by-Section Report

1. Disease Information

IMD82 is a Mendelian inborn error of immunity in which a single hyperactive kinase produces a combined phenotype of immunodeficiency, systemic autoinflammation, and B-cell lymphoma predisposition. - Key identifiers: OMIM #619381; MONDO:0030308; causal gene SYK (HGNC:11491). Orphanet, ICD-10/ICD-11, and MeSH-specific codes are not clearly established for this ultra-rare 2021-defined entity; it maps within IEI/combined immunodeficiency-with-associated-features categories. - Synonyms: "Immunodeficiency 82 with systemic inflammation"; "SYK gain-of-function disease"; "SYK-GOF immune dysregulation." - Information source: Aggregated disease-level resources (OMIM, IUIS classification) built from an individual-patient case series (n≈6) rather than large EHR datasets.

2. Etiology

3. Phenotypes

Phenotype Type HPO Onset Frequency (n≈6 cohort)
Colitis / IBD-like enteropathy Clinical sign HP:0002583 Childhood/very-early-onset Core feature
Arthritis Clinical sign HP:0001369 Childhood Core feature
Dermatitis Physical manifestation HP:0011123 Childhood Core feature
Immunodeficiency (infection susceptibility) Clinical/lab HP:0002715 Childhood Core feature
Diffuse large B-cell lymphoma Neoplasm HP:0004297 Childhood–young adult Reported in cohort

Severity is variable and can be severe/refractory; progression includes both chronic inflammation and episodic flares plus a serious oncologic complication (DLBCL). Quality-of-life impact is substantial (chronic multi-organ inflammation, malignancy risk, treatment burden), though formal EQ-5D/SF-36 data are unavailable for this ultra-rare disease (PMID: 33782605).

4. Genetic / Molecular Information

5. Environmental Information

No established environmental, lifestyle, or infectious causes. The disease is monogenic. Because SYK sits downstream of pattern-recognition and Fc/C-type-lectin receptors, microbial and antigenic exposures are plausible amplifiers of inflammation but are not demonstrated drivers.

6. Mechanism / Pathophysiology

Presented above as the ordered causal chain and schematic. In brief: a SYK GOF variant disrupts kinase autoinhibition → constitutive ITAM-coupled signaling (PLCγ2, PI3K–AKT, MAPK/ERK, NF-κB) → branches into (A) multi-organ autoinflammation with paradoxical immunodeficiency and (B) tonic PI3K–AKT survival signaling predisposing to DLBCL. Key molecular pathways: B-cell receptor signaling (Reactome/KEGG), Fc receptor signaling, PI3K–AKT, MAPK, NF-κB. Cellular processes: inflammation, dysregulated lymphocyte/myeloid activation, and suppressed apoptosis/enhanced survival of B cells. Immune involvement spans both immunodeficiency and chronic inflammation — a hallmark of immune-dysregulation IEIs.

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

No formal survival statistics exist for this ultra-rare entity. Prognosis is shaped by (a) severity/refractoriness of multi-organ inflammation and (b) the serious complication of DLBCL, which historically carries substantial mortality. The identification of a druggable, hematopoietically restricted target materially improves the outlook, since SYK inhibition or HSCT can address the root cause (mouse-model rescue, PMID: 33782605). Prognostic biomarkers plausibly include SYK/BCR signaling intensity, given its correlation with aggressive B-cell lymphoma behavior (PMID: 38503806).

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Evidence Base

PMID Title (abbrev.) Role in this report
33782605 Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation (Nat Genet 2021) Defining paper. Establishes monoallelic SYK GOF, clinical triad, mouse model, and therapeutic rescue (SYK inhibitor / WT BMT).
23154170 Structural and biophysical characterization of the Syk activation switch Structural basis: full-length SYK autoinhibition and the pITAM/autophosphorylation activation switch disrupted by GOF variants.
35398488 SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies Mechanistic link: SYK-driven tonic PI3K signaling promotes survival over cell death — basis for lymphoma predisposition.
38503806 BCR signaling activity identifies higher-risk MCL patients High SYK/BCR signaling predicts aggressive B-cell lymphoma behavior; supports Branch B.
41608114 Human inborn errors of immunity: 2024 IUIS update Situates IMD82/SYK within the formal IEI classification used for diagnosis.
42026764 Syk inhibition limits autoimmunity in B-cell TRAF3-deficient mice Class-level support that fostamatinib corrects SYK-driven B-cell dysfunction/autoimmunity.
40903253 Future directions in warm AIHA management Fostamatinib as an established, efficacious SYK inhibitor in immune disease.
40962713 Fostamatinib and acute aortic dissection in ITP Safety caveat for chronic SYK inhibition.
31356155 Chemical-genetics SYK mouse model Complementary tool confirming SYK-dependent BCR signaling.
25682127 SYK molecular evolution in lamprey Evolutionary conservation of SYK tandem-SH2/kinase architecture.

Evidence-source types: Human clinical (P33782605 case series; IUIS classification 41608114); model organism (33782605 mouse; 42026764; 31356155); in vitro/structural (23154170; 35398488); lymphoma clinical correlation (38503806).

Limitations and Knowledge Gaps

  1. Tiny cohort (n≈6): All core clinical claims rest on a single 2021 case series. Penetrance, expressivity, sex ratio, natural history, and quantitative phenotype frequencies cannot be reliably estimated.
  2. No epidemiology: Prevalence/incidence are unknown; the disease is ultra-rare with no registry data.
  3. Branch B is partly inferred: The lymphoma-predisposition mechanism is supported by strong SYK/BCR biology (PMID: 35398488; PMID: 38503806) but has not been dissected specifically in IMD82 patient B cells at scale.
  4. Variant spectrum incomplete: Only a few variants (notably p.Ser550Tyr) are characterized; the full allelic series and genotype–phenotype correlations are undefined.
  5. Therapeutic evidence is preclinical: SYK-inhibitor/BMT rescue is demonstrated in mice; human treatment outcomes for IMD82 specifically are anecdotal, and fostamatinib carries vascular/thrombotic safety concerns (PMID: 40962713).
  6. No omics depth: Patient-level transcriptomic, proteomic, metabolomic, or single-cell data for IMD82 are not available in the reviewed literature.
  7. Missing ontology/registry codes: Orphanet/ICD/MeSH-specific mappings are not firmly established for this recently defined entity.

Proposed Follow-up Experiments / Actions

  1. Establish an international IMD82 patient registry with genotype, functional pSYK data, longitudinal inflammation scores, and lymphoma incidence to define natural history, penetrance, and expressivity.
  2. Expand and functionally classify the SYK variant allelic series (deep mutational scanning across the tSH2/interdomain-A/kinase regions) to build a genotype–phenotype and pSYK-activity map for variant interpretation (ACMG PS3 functional evidence).
  3. Single-cell multi-omics of patient PBMC/gut/lymphoma tissue to resolve which cell types (B cells vs myeloid) drive Branch A vs Branch B and to identify predictive biomarkers.
  4. Prospective, biomarker-guided fostamatinib trial in IMD82 (with cardiovascular safety monitoring per PMID: 40962713), including pSYK/PI3K-AKT pharmacodynamic readouts.
  5. Define HSCT indications and outcomes for severe/lymphoma-associated IMD82, leveraging the mouse WT-BMT rescue as rationale.
  6. Test whether early SYK inhibition reduces lymphoma incidence in the Syk-Ser544Tyr knock-in model (chemoprevention proof-of-concept).
  7. Formalize ontology/registry entries (Orphanet, ICD-11, MeSH) and curate HPO frequency annotations as new cases accrue.

Report compiled from 6 confirmed findings and 32 reviewed papers over 5 investigation iterations. Evidence source types are distinguished throughout as human clinical, model organism, in vitro/structural, or computational.